All News

Busy pharmacists looking to achieve their health goals for 2018 should look no further than their cell phones.

With the New Year on our heels, let’s look back on some of the most noteworthy FDA approvals of 2017.

A look at the most popular videos on The American Journal of Pharmacy Benefits over the past year.

A look back at the debate around direct and indirect remuneration fees in 2017.

Ertugliflozin (Steglatro) is also approved as part of 2 fixed-dose combinations.

Enzymes that protect the immune system may malfunction and provoke cancer-related mutations.

Why I included a computer coding aspect into my APPE rotation

What my experience in pharmacy, jazz piano and language studies have in common

A look at the most-read pharmacy benefit manager articles published on The American Journal of Pharmacy Benefits in 2017.

A review of the most popular video interviews on Specialty Pharmacy Times.

Pembrolizumab plus trastuzumab may overcome drug-resistance among patients with advanced HER2+ breast cancer.

The market for disease-modifying multiple sclerosis drugs is projected to reach $25.3 billion by 2026, according to a new report.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Make a commitment to make the workplace a cleaner, happier, and healthier place in 2018.

Abbott has released its newest system for type 1 and 2 diabetes.

This is the first part of a series on how pharmacy professionals have been depicted on TV, both in a positive and negative manner.

Paclitaxel plus nintedanib overcomes chemotherapy-resistance in endometrial cancer.

Top articles of the week from The American Journal of Pharmacy Benefits.

Top news of the week from Specialty Pharmacy Times.

Inhibiting a protein kinase may improve the efficacy of radiation in glioblastoma.

Significant opportunities exist for the development of new drugs for relapsing remitting multiple sclerosis.

If one-quarter of HIV-negative patients took PrEP, a significant amount of new HIV infections could be prevented.

Huntington’s disease may be linked to a toxic build-up of urea in the brain.

Trastuzumab is an oncology biologic drug that is indicated for multiple types of cancer.

Hydroxyurea is indicated to decrease the prevalence of painful crises and the need for transfusions in pediatric patients aged 2 years and older with sickle cell anemia with moderate-to-severe painful crises.

The FDA recently approved nivolumab (Opdivo) for the treatment of patients with melanoma whose disease has spread to the lymph nodes or those with metastatic disease who have undergone resection, according to a press release.

Officials with the FDA recently approved cabozantinib (Cabometyx) for the first-line treatment of patients with advanced renal cell carcinoma (RCC), according to a press release.

Officials with the FDA granted accelerated approval to bosutinib (Bosulif) for the treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

Now that Eli Lilly is looking to create a closed-loop system for diabetes management, does that mean this product will soon be available?